**Supplementary Table 1. The T100 articles in the field of CRPC research**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Rank | Author | Title | Journal | IF | Year | TC | AC/Y |
| 1 | Tannock IF et al. | Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer | New England Journal of Medicine | 74.699 | 2004 | 3594 | 239.60  |
| 2  | Kantoff PW et al. | Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer | New England Journal of Medicine | 74.699 | 2010 | 2854 | 317.11  |
| 3 | Petrylak DP et al. | Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer | New England Journal of Medicine | 74.699 | 2004 | 2522 | 168.13  |
| 4  | De Bono JS et al. | Abiraterone and Increased Survival in Metastatic Prostate Cancer | New England Journal of Medicine | 74.699 | 2011 | 2237 | 279.63  |
| 5  | Scher HI et al. | Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy | New England Journal of Medicine | 74.699 | 2012 | 2060 | 294.29  |
| 6  | De Bono JS et al. | Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial | Lancet | 60.39 | 2010 | 1760 | 195.56  |
| 7 | Feldman BJ et al. | The development of androgen-independent prostate cancer | Nature Reviews Cancer | 53.03 | 2001 | 1626 | 90.33  |
| 8  | Ryan CJ et al. | Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy | New England Journal of Medicine | 74.699 | 2013 | 1360 | 226.67  |
| 9  | Parker C et al. | Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer | New England Journal of Medicine | 74.699 | 2013 | 1268 | 211.33  |
| 10 | Tannock IF et al. | Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points | Journal of Clinical Oncology | 32.956 | 1996 | 1199 | 52.13  |
| 11  | Tran C et al. | Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer | Science | 41.846 | 2009 | 1185 | 118.50  |
| 12 | De Bono JS et al. | Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer | Clinical Cancer Research | 10.107 | 2008 | 1206 | 109.64  |
| 13  | Grasso CS et al. | The mutational landscape of lethal castration-resistant prostate cancer | Nature | 42.779 | 2012 | 1094 | 156.29  |
| 14 | Saad F et al. | A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma | JNCI Journal of The National Cancer Institute | 11.577 | 2002 | 1077 | 63.35  |
| 15  | Antonarakis ES et al. | AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer | New England Journal of Medicine | 74.699 | 2014 | 1055 | 211.00  |
| 16  | Fizazi K et al. | Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study | Lancet | 60.39 | 2011 | 1021 | 127.63  |
| 17 | Mcdonnell TJ et al. | Expression of the protooncogene BCL-2 in the prostate and its association with emergence of androgen-independent prostate-cancer | Cancer Research | 9.727 | 1992 | 1027 | 38.04  |
| 18 | Heinlein CA et al. | Androgen receptor in prostate cancer | Endocrine Reviews | 14.661 | 2004 | 959 | 63.93  |
| 19  | Robinson D et al. | Integrative Clinical Genomics of Advanced Prostate Cancer | Cell | 38.637 | 2015 | 942 | 235.50  |
| 20 | Taplin ME et al. | Mutation of the androgen-receptor gene in metastatic androgen-independent prostate-cancer | New England Journal of Medicine | 74.699 | 1995 | 899 | 37.46  |
| 21 | Montgomery RB et al. | Maintenance of intratumoral androgens in metastatic prostate cancer: A mechanism for castration-resistant tumor growth | Cancer Research | 9.727 | 2008 | 824 | 74.91  |
| 22 | Bubley GJ et al. | Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the prostate-specific antigen working group | Journal of Clinical Oncology | 32.956 | 1999 | 792 | 39.60  |
| 23 | Craft N et al. | A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase | Nature Medicine | 36.13 | 1999 | 751 | 37.55  |
| 24 | Saad F et al. | Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer | JNCI Journal of The National Cancer Institute | 11.577 | 2004 | 746 | 49.73  |
| 25 | Small EJ et al. | Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer | Journal of Clinical Oncology | 32.956 | 2006 | 736 | 56.62  |
| 26  | Heidenreich A et al. | EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer | European Urology | 18.728 | 2014 | 717 | 143.40  |
| 27 | Berthold DR et al. | Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX 327 study | Journal of Clinical Oncology | 32.956 | 2018 | 689 | 689.00  |
| 28 | Scher HI et al. | Biology of progressive, castration-resistant prostate cancer: Directed therapies targeting the androgen-receptor signaling axis | Journal of Clinical Oncology | 232.956 | 2005 | 693 | 49.50  |
| 29  | Fizazi K et al. | Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study | Lancet Oncology | 33.752 | 2012 | 676 | 96.57  |
| 30  | Scher HI et al. | Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study | Lancet | 60.39 | 2010 | 684 | 76.00  |
| 31  | Mateo J et al. | DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer | New England Journal of Medicine | 74.699 | 2015 | 679 | 169.75  |
| 32 | Kantoff PW et al. | Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: Results of the Cancer and Leukemia Group B 9182 study | Journal of Clinical Oncology | 32.956 | 1999 | 668 | 33.40  |
| 33  | Kantoff PW et al. | Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer | Journal of Clinical Oncology | 32.956 | 2010 | 625 | 69.44  |
| 34 | Colombel M et al. | Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers | American Journal of Pathology | 3.491 | 1993 | 607 | 23.35  |
| 35 | Attard G et al. | Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven | Journal of Clinical Oncology | 32.956 | 2003 | 591 | 36.94  |
| 36  | Kwon ED et al. | Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial | Lancet Oncology | 33.752 | 2014 | 547 | 109.40  |
| 37  | Hu R et al. | Ligand-Independent Androgen Receptor Variants Derived from Splicing of Cryptic Exons Signify Hormone-Refractory Prostate Cancer | Cancer Research | 9.727 | 2009 | 552 | 55.20  |
| 38 | Linja MJ et al. | Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer | Cancer Research | 9.727 | 2001 | 536 | 29.78  |
| 39  | Wang Q et al. | Androgen Receptor Regulates a Distinct Transcription Program in Androgen-Independent Prostate Cancer | Cell | 38.637 | 2009 | 540 | 54.00  |
| 40 | Thalmann GN et al. | Androgen-independent cancer progression and bone metastasis in the lncap model of human prostate-cancer | Cancer Research | 9.727 | 1994 | 532 | 21.28  |
| 41 | Locke JA et al. | Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer | Cancer Research | 9.727 | 2008 | 484 | 44.00  |
| 42 | Nelson JB et al. | Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate | Nature Medicine | 36.13 | 1995 | 469 | 19.54  |
| 43 | Halabi S et al. | Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer | Journal of Clinical Oncology | 32.956 | 2003 | 479 | 29.94  |
| 44 | Small EJ et al. | Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells | Journal of Clinical Oncology | 32.956 | 2000 | 453 | 23.84  |
| 45  | Ryan CJ et al. | Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study | Lancet Oncology | 33.752 | 2015 | 455 | 113.75  |
| 46 | Raffo AJ et al. | Overexpression of bcl-2 protects prostate-cancer cells from apoptosis in-vitro and confers resistance to androgen depletion in-vivo | Cancer Research | 9.727 | 1995 | 450 | 18.75  |
| 47 | Gioeli D et al. | Activation of mitogen-activated protein kinase associated with prostate cancer progression | Cancer Research | 9.727 | 1999 | 439 | 21.95  |
| 48 | Shah RB et al. | Androgen-independent prostate cancer is a heterogeneous group of diseases: Lessons from a rapid autopsy program | Cancer Research | 9.727 | 2004 | 434 | 28.93  |
| 49  | Smith MR et al. | Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial | Lancet | 60.39 | 2012 | 426 | 60.86  |
| 50  | Attard G et al. | Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer | Journal of Clinical Oncology | 32.956 | 2009 | 429 | 42.90  |
| 51  | Sun S et al. | Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant | Journal of Clinical Investigation | 11.864 | 2010 | 420 | 46.67  |
| 52 | Grossmann ME et al. | Androgen receptor signaling in androgen-refractory prostate cancer | JNCI-Journal of The National Cancer Institute | 11.577 | 2001 | 401 | 22.28  |
| 53 | Navone NM et al. | P53 protein accumulation and gene mutation in the progression of human prostate carcinoma | JNCI Journal of The National Cancer Institute | 11.577 | 1993 | 416 | 16.00  |
| 54  | Mottet N et al. | EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer | European Urology | 18.728 | 2011 | 401 | 50.13  |
| 55  | Attard G et al. | Characterization of ERG, AR and PTEN Gene Status in Circulating Tumor Cells from Patients with Castration-Resistant Prostate Cancer | Cancer Research | 9.727 | 2009 | 397 | 39.70  |
| 56 | Debes JD et al. | Mechanisms of androgen-refractory prostate cancer | New England Journal of Medicine | 74.699 | 2004 | 385 | 25.67  |
| 57 | Small EJ et al. | Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: A phase III trial (CALGB 9583) | Journal of Clinical Oncology | 32.956 | 2004 | 385 | 25.67  |
| 58  | Watson PA et al. | Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor | Proceedings of The National Academy of Sciences of The United States of America | 9.412 | 2010 | 380 | 42.22  |
| 59 | Nakatani K et al. | Up-regulation of Akt3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines | Journal of Biological Chemistry | 4.238 | 1999 | 379 | 18.95  |
| 60  | Asangani IA et al. | Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer | Nature | 42.779 | 2014 | 374 | 74.80  |
| 61  | Xu K et al. | EZH2 Oncogenic Activity in Castration-Resistant Prostate Cancer Cells Is Polycomb-Independent | Science | 41.846 | 2012 | 367 | 52.43  |
| 62 | Zhao XY et al. | Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor | Nature Medicine | 36.13 | 2000 | 371 | 19.53  |
| 63  | Scher HI et al. | Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data | Lancet Oncology | 33.752 | 2009 | 373 | 37.30  |
| 64  | Mostaghel EA et al. | Resistance to CYP17A1 Inhibition with Abiraterone in Castration-Resistant Prostate Cancer: Induction of Steroidogenesis and Androgen Receptor Splice Variants | Clinical Cancer Research | 10.107 | 2011 | 368 | 46.00  |
| 65 | Kwok WK et al. | Up-regulation of TWIST in prostate cancer and its implication as a therapeutic target | Cancer Research | 9.727 | 2005 | 334 | 23.86  |
| 66 | Papandreou CN et al. | Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer | Journal of Clinical Oncology | 32.956 | 2004 | 361 | 24.07  |
| 67 | Armstrong AJ et al. | Circulating Tumor Cells from Patients with Advanced Prostate and Breast Cancer Display Both Epithelial and Mesenchymal Markers | Molecular Cancer Research | 4.63 | 2011 | 357 | 44.63  |
| 68 | Yagoda A et al. | Cytotoxic chemotherapy for advanced hormone-resistant prostate-cancer | Cancer | 5.772 | 1993 | 349 | 13.42  |
| 69 | Cher ML et al. | Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping | Cancer Research | 9.727 | 1996 | 358 | 15.57  |
| 70 | Wen Y et al. | HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway | Cancer Research | 9.727 | 2000 | 350 | 18.42  |
| 71 | Mostaghel EA et al. | Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: Therapeutic implications for castration-resistant prostate cancer | Cancer Research | 9.727 | 2007 | 352 | 29.33  |
| 72 | Shi XB et al. | An androgen-regulated miRNA suppresses Bak1 expression and induces androgen-independent growth of prostate cancer cells | Proceedings of The National Academy of Sciences of The United States of America | 9.412 | 2007 | 330 | 27.50  |
| 73  | Yang L et al. | lncRNA-dependent mechanisms of androgen-receptor-regulated gene activation programs | Nature | 42.779 | 2013 | 313 | 52.17  |
| 74  | Beltran H et al. | Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug Targets | Cancer Discovery | 29.497 | 2011 | 339 | 42.38  |
| 75 | Zegarra-Moro OL et al. | Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells | Cancer Research | 9.727 | 2002 | 339 | 19.94  |
| 76  | Beltran H et al. | Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer | Nature Medicine | 36.13 | 2016 | 339 | 113.00  |
| 77  | Harris WP et al. | Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion | Nature Clinical Practice Urology | 0 | 2009 | 337 | 33.70  |
| 78 | Halkidou K et al. | Upregulation and nuclear recruitment of HDACI in hormone refractory prostate cancer | Prostate | 3.279 | 2004 | 320 | 21.33  |
| 79  | Li Y et al. | Androgen Receptor Splice Variants Mediate Enzalutamide Resistance in Castration-Resistant Prostate Cancer Cell Lines | Cancer Research | 9.727 | 2013 | 327 | 54.50  |
| 80 | Di Lorenzo G et al. | Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer | Clinical Cancer Research | 10.107 | 2002 | 326 | 19.18  |
| 81  | Cornford P et al. | EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer | European Urology | 18.728 | 2017 | 314 | 157.00  |
| 82  | Danila DC et al. | Phase II Multicenter Study of Abiraterone Acetate Plus Prednisone Therapy in Patients With Docetaxel-Treated Castration-Resistant Prostate Cancer | Journal of Clinical Oncology | 32.956 | 2010 | 312 | 34.67  |
| 83 | Nilsson S et al. | Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study | Lancet Oncology | 33.752 | 2007 | 314 | 26.17  |
| 84 | Dieli F et al. | Targeting human gamma delta T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer | Cancer Research | 9.727 | 2007 | 311 | 25.92  |
| 85 | Nakahara T et al. | YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts | Cancer Research | 9.727 | 2007 | 303 | 25.25  |
| 86 | Kelly WK et al. | Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate-cancer | Journal of Clinical Oncology | 32.956 | 1993 | 312 | 12.00  |
| 87  | Slovin SF et al. | Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study | Annals of Oncology | 18.274 | 2013 | 299 | 49.83  |
| 88 | Graff JR et al. | Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27(Kip1) expression | Journal of Biological Chemistry | 4.238 | 2000 | 309 | 16.26  |
| 89 | Lin SL et al. | Loss of mir-146a function in hormone-refractory prostate cancer | RNA A Publication of The RNA Society | 4.32 | 2008 | 291 | 26.45  |
| 90  | Clegg NJ et al. | ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment | Cancer Research | 9.727 | 2012 | 302 | 43.14  |
| 91 | Ammirante M et al. | B-cell-derived lymphotoxin promotes castration-resistant prostate cancer | Nature | 42.779 | 2010 | 295 | 32.78  |
| 92 | Kinkade CW et al. | Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model | Journal of Clinical Investigation | 11.864 | 2008 | 297 | 27.00  |
| 93 | Tilley WD et al. | Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence | Clinical Cancer Research | 10.107 | 1996 | 297 | 12.91  |
| 94  | Reid AHM et al. | Significant and Sustained Antitumor Activity in Post-Docetaxel, Castration-Resistant Prostate Cancer With the CYP17 Inhibitor Abiraterone Acetate | Journal of Clinical Oncology | 32.956 | 2010 | 296 | 32.89  |
| 95 | Klein KA et al. | Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice | Nature Medicine | 36.13 | 1997 | 299 | 13.59  |
| 96  | Hu R et al. | Distinct Transcriptional Programs Mediated by the Ligand-Dependent Full-Length Androgen Receptor and Its Splice Variants in Castration-Resistant Prostate Cancer | Cancer Research | 9.727 | 2012 | 295 | 42.14  |
| 97 | Bander NH et al. | Phase I trial of (177)lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer | Journal of Clinical Oncology | 32.956 | 2005 | 290 | 20.71  |
| 98 | Carducci MA et al. | Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: A randomized, phase II, placebo-controlled trial | Journal of Clinical Oncology | 32.956 | 2003 | 283 | 17.69  |
| 99 | Andersen RJ et al. | Regression of Castrate-Recurrent Prostate Cancer by a Small-Molecule Inhibitor of the Amino-Terminus Domain of the Androgen Receptor | Cancer Cell  | 26.602 | 2010 | 292 | 32.44  |
| 100 | Taplin ME et al. | Androgen receptor: A key molecule in the progression of prostate cancer to hormone independence | Journal of Cellular Biochemistry | 4.237 | 2004 | 282 | 18.80  |

TC,: total citations; AC/Y, average citations per year.